News

A new partnership with Thailand to share the expertise of genome sequencing, research collaboration, education and training opportunities, as well as genomics data handling will help UK patients. A MoU has been inked between deputy Prime Minister of Thailand, Anutin...

There was a pin-drop silence in the conference room. A senior executive from a multinational pharma company had asked me a question; “Which digital platform do you think is the best?” His US headquartered boss wanted him to prioritize digital...

According to a survey from Fitch Solutions, South Korea's pharmaceutical market attractiveness is expected to stay strong despite ongoing concerns about the country's slow pace of drug authorizations. According to the analysis, the pharmaceutical business will remain competitive due to...

FDA has recently announced that it is going to restart its in-person meetings that are face-to-face beginning February 13 with industry sponsors of biologics and drugs. This step is taken after a shift took place toward all virtual meetings...

A novel strategy for 2023–25 adopted by the Medicines Patent Pool looks to lessen the inequalities in access by way of enhancing the affordability as well as availability of health products across low- and-middle-income countries (LMIC). The MPP which is...

The European Commission (EC) has granted marketing authorisation for Regeneron Pharmaceuticals and Sanofi’s Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE). Dupixent’s expanded authorisation in the European Union (EU) is intended to treat 12 years and older patients with EoE, who...

Seqens Group opens the Seqens Boston R&D Center, a state-of-the-art, 15,000 square-foot R&D center in Devens, Mass. that serves as one of the company’s global centers of excellence. The new facility will bring customers advanced capabilities for the discovery...